Oxford Immunotec Global PLC (OXFD)
(Delayed Data from NSDQ)
$16.54 USD
+0.35 (2.16%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.54 USD
+0.35 (2.16%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here's Why You Should Hold on to PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
Oxford Immunotec (OXFD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 70.00% and 6.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Oxford Immunotec (OXFD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Oxford Immunotec (OXFD) a New Buy Stock
by Zacks Equity Research
Oxford Immunotec (OXFD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks.com featured highlights include: Great Lakes, Oxford Immunotec, DSP, Telenav and Osisko
by Zacks Equity Research
Zacks.com featured highlights include: Great Lakes, Oxford Immunotec, DSP, Telenav and Osisko
5 Great Breakout Stocks Offering Stunning Returns
by Swarup Gupta
Selecting breakout stocks is probably one of the most favored techniques among active investors.
Moving Average Crossover Alert: Oxford Immunotec Global
by Zacks Equity Research
Oxford Immunotec Global PLC (OXFD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Oxford Immunotec (OXFD) Beats Q4 Earnings Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 757.89% and -17.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Oxford Immunotec (OXFD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -140.00% and -52.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Oxford Immunotec (OXFD) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Oxford Immunotec (OXFD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com highlights: General Finance, Northern Oil and Gas, American Outdoor Brands, Amber Road and Oxford Immunotec Global
by Zacks Equity Research
Zacks.com highlights: General Finance, Northern Oil and Gas, American Outdoor Brands, Amber Road and Oxford Immunotec Global
Quest Diagnostics Plans a Buyout to Widen TB Testing Suite
by Zacks Equity Research
Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.
5 Cheap Breakout Stocks for Stellar Returns
by Swarup Gupta
The key to this kind of stock selection is to identify stocks which are trading within a narrow band.
Oxford Immunotec (OXFD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -4.17% and 2.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Momentum Stocks to Buy for March 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 26th:
5 Medtech Stocks to Steer Clear of Amid Political Chaos
by Zacks Equity Research
In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.